<DOC>
	<DOCNO>NCT00025064</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Peripheral stem cell transplant may able replace immune cell destroy chemotherapy . PURPOSE : This phase II trial study well combination chemotherapy regimens without radiation therapy peripheral stem cell transplant work treat child Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Radiation Therapy Peripheral Stem Cell Transplant Treating Children With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether current survival figure maintain long-term sequela treatment minimize child adolescent stage I-III Hodgkin 's lymphoma receiving follow regimen , reduces exposure chemotherapy radiotherapy : chlorambucil , vinblastine , prednisolone , procarbazine ( ChIVPP ) doxorubicin , bleomycin , vincristine , dacarbazine ( ABVD ) etoposide , prednisolone , ifosfamide , cisplatin ( EPIC ) , radiotherapy , high-dose melphalan , and/or autologous peripheral blood stem cell transplantation ( APBSCT ) . - Determine whether survival figure improve child adolescent stage IV Hodgkin 's lymphoma inadequate response initial therapy receive ChIVPP ABVD EPIC , radiotherapy , high-dose melphalan , APBSCT . OUTLINE : This multicenter study . Patients assign 1 3 treatment group base disease status . - Group 1 ( stage I disease ) : All patient mixed cellularity young patient subtype assign subgroup A . Older patient without mixed cellularity assign subgroup A B base decision physicians patients/parents . Subgroup A : Patients receive 2 course hybrid regimen . One course hybrid regimen comprises regimen ChIVPP follow regimen ABVD . Regimen ChIVPP comprise vinblastine IV day 1 8 oral chlorambucil , oral procarbazine , oral prednisolone ( PRDL ) daily day 1-14 . Regimen ABVD comprise doxorubicin IV 6 hour , bleomycin IV 15-30 minute , vincristine IV , dacarbazine IV 15 minute day 1 14 . Patients relapsed disease receive etoposide IV 1 hour day 1-4 , oral PRDL ifosfamide IV 1 hour day 1-5 , cisplatin IV 24 hour day 10 ( EPIC ) . Treatment EPIC continue every 3 week total 6 course . Patients undergo radiotherapy . Patients poor response radiotherapy receive consolidation high-dose melphalan ( L-PAM ) IV 30-90 minute , follow least 12 hour later autologous peripheral blood stem cell transplantation ( APBSCT ) ( bone marrow involvement time relapse ) . Subgroup B : Patients subgroup A may either receive chemotherapy outline radiotherapy depend clinician patient discussion . Patients relapse disease radiotherapy receive 3 course hybrid regimen . If relapse occurs outside initial radiotherapy field , radiotherapy administer . - Group 2 ( stage II III disease ) : Patients receive 3 course hybrid regimen . Patients relapsed disease receive 4 course EPIC . Patients complete remission ( CR ) good partial remission ( GPR ) fourth course EPIC receive 2 additional course EPIC follow radiotherapy . Patients without CR GPR fourth course EPIC undergo radiotherapy follow L-PAM APBSCT group 1 , subgroup A . - Group 3 ( stage IV inadequate response initial therapy ) : Patients receive 2 course hybrid regimen . Patients CR GPR second course ABVD assign subgroup C. Patients without CR GPR second course ABVD assign subgroup D. Subgroup C : Patients receive 2 additional course hybrid regimen . Patients relapse disease fourth course ABVD receive 4 course EPIC follow radiotherapy , L-PAM , APBSCT group 1 , subgroup A. Subgroup D : Patients receive 4 course EPIC follow radiotherapy , L-PAM , APBSCT group 1 , subgroup A . Patients follow every 2 month 1 year , every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 260 patient ( 75 stage I disease , 150 stage II III disease , 35 stage IV disease ) accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's lymphoma Stage IIV No posttransplantation Hodgkin 's lymphoma Mediastinal syndrome allow PATIENT CHARACTERISTICS : Age : Under 18 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No previously treat malignancy No DNA repair defect syndromes PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
</DOC>